# RedChemExpress

## Product Data Sheet

## Rafivirumab

Cat. No.:	HY-P99811
CAS No.:	944548-37-2
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY				
Description	. ,	Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails <sup>[1][2][3]</sup> .		
In Vitro	Rafivirumab binds to a Rafivirumab fully neuti	Rafivirumab shows neutralization effect against series of RABV isolates <sup>[2]</sup> . Rafivirumab binds to antigenic site I of the RABV glycoprotein <sup>[3]</sup> . Rafivirumab fully neutralizs the wild type ERA <sub>439</sub> and N336D R346K with EC <sub>50</sub> ranging between 3 and 5 pg/mL <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo		Rafivirumab (3-12 μg/kg,i.m.) together with CR4098 increases survival in syrian hamsters infected with bat rabies viruses <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Syrian hamsters infected with bat rabies viruses <sup>[2]</sup> .		
	Dosage:	6, 12, 16, 18 or 24 $\mu g/kg$ of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio)		
	Administration:	i.m.		
	Result:	Increased survival rate.		
	Result:	Increased survival rate.		

#### REFERENCES

[1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45.

[2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48.

[3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.

### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA